A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
Kathleen N. Moore(University of Oklahoma Medical Center), Johanna C. Bendell(Dana-Farber Cancer Institute), Erika S. Wittchen(University of North Carolina at Chapel Hill), David S. Hong(The University of Texas MD Anderson Cancer Center), Judy S. Wang(Sarah Cannon), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Suzanne F. Jones(Sarah Cannon), Shubham Pant(The University of Texas MD Anderson Cancer Center), Xuejing Wang(University of Bern), Raid Aljumaily(Sarah Cannon), Erika Hamilton(Sarah Cannon), Aimee Bence Lin(Eli Lilly (United States)), Manish R. Patel(Sarah Cannon)
Cited by 25
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817